Pioneering Drug Development for Hearing Loss with Dr. Jonathan Kil

In this episode, we welcome Dr. Jonathan Kil, the CEO and CMO of Sound Pharmaceuticals to discuss the latest developments in hearing loss treatment. With a distinguished background in auditory neuroscience and otolaryngology, Dr. Kil co-founded Sound Pharmaceuticals over 22 years ago with a mission to develop drug-based therapies for sensorineural hearing loss and tinnitus. He has led the company’s research and development strategy, securing numerous NIH and Department of Defense awards, and spearheading numerous clinical studies.
Dr. Kil recounts the journey of Sound Pharmaceuticals over the past two decades, highlighting the challenges faced and milestones achieved. He focuses on the development of SPI-1005, an investigational drug containing ebselen, a novel anti-inflammatory compound that mimics and induces the activity of Glutathione Peroxidase, an enzyme critical to hearing and balance. Currently in clinical trials, SPI-1005 has shown safety and efficacy in treating three different forms of acquired sensorineural hearing loss in adults: loud sound exposure or acute noise-induced hearing loss, Meniere's disease, and antibiotic-induced ototoxicity.
Dr. Kil explains the science behind these innovative therapies, the potential impact they may have, and the rigorous steps being taken to bring them to market. The conversation provides a unique perspective on the current state and future of pharmaceutical treatments for hearing loss and other inner ear conditions.
Learn more about Sound Pharmaceuticals here: soundpharma.com/
Be sure to subscribe to our KZbin channel for the latest episodes each week, and follow This Week in Hearing on LinkedIn and X (formerly Twitter):
/ this-week-in-hearing
/ weekinhearing
Audio podcast can be found on all major platforms, including Apple & Spotify: podcasters.spotify.com/pod/sh...
TIMESTAMPS
00:00 Introduction and Background
02:46 Small molecule approach: SPI-1005
04:07 Meniere's disease
05:15 Noise induced hearing loss
05:55 Cystic fibrosis and ototoxicity
06:53 Cochlear implant collaboration with MED-EL
08:16 Challenges of treatment development for hearing loss and tinnitus
17:43 Role of audiologist and ENT physician in patient management
24:22 AI applications in therapeutic development
26:02 Personal hearing loss experience
30:10 Current timeline and future developments